Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 443

1.

Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.

Fakkert IE, Jansen L, Meijer K, Kok T, Oosterwijk JC, Mourits MJ, de Bock GH.

Breast Cancer Res Treat. 2011 Aug;129(1):157-64. doi: 10.1007/s10549-011-1423-4. Epub 2011 Mar 4.

PMID:
21373873
2.

Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.

Fakkert IE, Mourits MJ, Jansen L, van der Kolk DM, Meijer K, Oosterwijk JC, van der Vegt B, Greuter MJ, de Bock GH.

Cancer Prev Res (Phila). 2012 Nov;5(11):1291-7. doi: 10.1158/1940-6207.CAPR-12-0190. Epub 2012 Sep 25.

3.

Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.

Kim SI, Lim MC, Lee DO, Kong SY, Seo SS, Kang S, Lee ES, Park SY.

J Cancer Res Clin Oncol. 2016 Jan;142(1):333-40. doi: 10.1007/s00432-015-2051-x. Epub 2015 Oct 5.

PMID:
26438354
4.

Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.

Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RM, Hill KA, Hoogerbrugge N, Wasser MN, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJ, Klijn JG, Plewes DB, Leach MO, de Koning HJ.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1458-68. doi: 10.1158/1055-9965.EPI-11-1196. Epub 2012 Jun 28.

5.

Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.

Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collée JM, van Doorn HC, Gomez Garcia EB, Kets CM, van Leeuwen FE, Meijers-Heijboer HE, Mourits MJ, van Os TA, Vasen HF, Verhoef S, Rookus MA, Hooning MJ; Hereditary Breast and Ovarian Cancer Research Group Netherlands.

J Natl Cancer Inst. 2015 Mar 18;107(5). pii: djv033. doi: 10.1093/jnci/djv033. Print 2015 May.

PMID:
25788320
6.

Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA.

J Clin Oncol. 2005 Oct 20;23(30):7491-6.

PMID:
16234515
7.

Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.

van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJ, de Vries J, van der Hout AH, Oosterwijk JC.

Breast Cancer Res Treat. 2010 Dec;124(3):643-51. doi: 10.1007/s10549-010-0805-3. Epub 2010 Mar 4.

PMID:
20204502
8.

Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.

Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Tung N, Weitzel JN, Couch FJ, Hulick PJ, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Blum JL, Domchek SM, Chen J, Rebbeck TR.

Breast Cancer Res Treat. 2014 Nov;148(2):397-406. doi: 10.1007/s10549-014-3134-0. Epub 2014 Oct 14.

9.

Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.

Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim-Sing C, Isaacs C, Domchek S, Sun P; Hereditary Breast Cancer Clinical Study Group.

Lancet Oncol. 2006 May;7(5):402-6. Erratum in: Lancet Oncol. 2006 Jun;7(6):453. Domcheck, Susan [corrected to Domchek, Susan].

PMID:
16648044
10.

Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.

Giannakeas V, Lubinski J, Gronwald J, Moller P, Armel S, Lynch HT, Foulkes WD, Kim-Sing C, Singer C, Neuhausen SL, Friedman E, Tung N, Senter L, Sun P, Narod SA.

Breast Cancer Res Treat. 2014 Aug;147(1):113-8. doi: 10.1007/s10549-014-3063-y. Epub 2014 Aug 1.

PMID:
25082516
11.

Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy.

van Verschuer VM, Heemskerk-Gerritsen BA, van Deurzen CH, Obdeijn IM, Tilanus-Linthorst MM, Verhoef C, Schmidt MK, Koppert LB, Hooning MJ, Seynaeve C.

Cancer Biol Ther. 2014 Apr;15(4):371-9. doi: 10.4161/cbt.27628. Epub 2014 Jan 14.

12.

Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.

Hirasawa A, Masuda K, Akahane T, Tsuruta T, Banno K, Makita K, Susumu N, Jinno H, Kitagawa Y, Sugano K, Kosaki K, Aoki D.

Jpn J Clin Oncol. 2013 May;43(5):515-9. doi: 10.1093/jjco/hyt036. Epub 2013 Mar 13.

PMID:
23487443
13.

Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy.

DeLeo MJ 3rd, Domchek SM, Kontos D, Conant E, Chen J, Weinstein S.

AJR Am J Roentgenol. 2015 Mar;204(3):669-73. doi: 10.2214/AJR.13.12146.

PMID:
25714301
14.

Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.

Kaas R, Verhoef S, Wesseling J, Rookus MA, Oldenburg HS, Peeters MJ, Rutgers EJ.

Ann Surg. 2010 Mar;251(3):488-92. doi: 10.1097/SLA.0b013e3181c3c36d.

PMID:
20134318
15.

Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.

Cibula D, Zikan M, Dusek L, Majek O.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1197-207. doi: 10.1586/era.11.38.

PMID:
21916573
16.

Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.

Botkin JR, Smith KR, Croyle RT, Baty BJ, Wylie JE, Dutson D, Chan A, Hamann HA, Lerman C, McDonald J, Venne V, Ward JH, Lyon E.

Am J Med Genet A. 2003 Apr 30;118A(3):201-9.

PMID:
12673648
17.

Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.

Kim D, Kang E, Hwang E, Sun Y, Hwang Y, Yom CK, Kim K, No JH, Kim YB, Kim SW.

Fam Cancer. 2013 Dec;12(4):621-8. doi: 10.1007/s10689-013-9625-z.

PMID:
23504064
18.

Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.

Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA.

JAMA. 2004 Sep 15;292(11):1317-25.

PMID:
15367553
19.

A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer.

Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, Griffiths A, Parker S, Houssami N.

Eur J Cancer. 2007 Sep;43(13):1905-17. Epub 2007 Aug 2. Review.

PMID:
17681781
20.

Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.

Rhiem K, Foth D, Wappenschmidt B, Gevensleben H, Büttner R, Ulrich U, Schmutzler RK.

Arch Gynecol Obstet. 2011 Mar;283(3):623-7. doi: 10.1007/s00404-010-1476-3. Epub 2010 Apr 29.

PMID:
20428881

Supplemental Content

Support Center